Bristol-Myers Squibb (BMY) Competitors

Bristol-Myers Squibb (NYSE:BMY) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations, media sentiment and community ranking.

Do analysts rate BMY or JNJ?

Bristol-Myers Squibb presently has a consensus price target of $56.27, suggesting a potential downside of 0.15%. Johnson & Johnson has a consensus price target of $174.29, suggesting a potential upside of 18.54%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, analysts clearly believe Johnson & Johnson is more favorable than Bristol-Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol-Myers Squibb	2 Sell rating(s)	13 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.29
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

Is BMY or JNJ a better dividend stock?

Bristol-Myers Squibb pays an annual dividend of $2.48 per share and has a dividend yield of 4.4%. Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.4%. Bristol-Myers Squibb pays out -69.1% of its earnings in the form of a dividend. Johnson & Johnson pays out 71.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has raised its dividend for 17 consecutive years and Johnson & Johnson has raised its dividend for 63 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

Does the media prefer BMY or JNJ?

In the previous week, Johnson & Johnson had 63 more articles in the media than Bristol-Myers Squibb. MarketBeat recorded 113 mentions for Johnson & Johnson and 50 mentions for Bristol-Myers Squibb. Bristol-Myers Squibb's average media sentiment score of 1.14 beat Johnson & Johnson's score of 0.95 indicating that Bristol-Myers Squibb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol-Myers Squibb	36 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Johnson & Johnson	79 Very Positive mention(s)	12 Positive mention(s)	15 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Positive

Which has higher valuation and earnings, BMY or JNJ?

Johnson & Johnson has higher revenue and earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol-Myers Squibb	$45.01B	2.54	$8.03B	-$3.59	-15.70
Johnson & Johnson	$85.16B	4.16	$35.15B	$6.91	21.28

Is BMY or JNJ more profitable?

Johnson & Johnson has a net margin of 19.14% compared to Bristol-Myers Squibb's net margin of -15.30%. Johnson & Johnson's return on equity of 35.45% beat Bristol-Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol-Myers Squibb	-15.30%	11.94%	2.51%
Johnson & Johnson	19.14%	35.45%	14.23%

Which has more volatility and risk, BMY or JNJ?

Bristol-Myers Squibb has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Does the MarketBeat Community prefer BMY or JNJ?

Johnson & Johnson received 28 more outperform votes than Bristol-Myers Squibb when rated by MarketBeat users. However, 66.22% of users gave Bristol-Myers Squibb an outperform vote while only 65.15% of users gave Johnson & Johnson an outperform vote.

Company	Underperform	Outperform
Bristol-Myers Squibb	Outperform Votes 1088 66.22%	Underperform Votes 555 33.78%
Johnson & Johnson	Outperform Votes 1116 65.15%	Underperform Votes 597 34.85%

Do institutionals & insiders hold more shares of BMY or JNJ?

76.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Johnson & Johnson beats Bristol-Myers Squibb on 16 of the 22 factors compared between the two stocks.